By Pancreatic cancer, long regarded as one of the deadliest forms of the disease, may be entering a new phase of treatment innovation, as early data from two experimental therapies show signs of improving outcomes in a cancer with a five-year survival rate of just 13%.
Researchers and clinicians on April 20 pointed to advances in two distinct approaches: a personalized mRNA vaccine designed to train the immune system to recognize tumors, and a targeted drug aimed at blocking a key genetic mutation that drives most pancreatic cancers.
The developments focus on pancreatic ductal adenocarcinoma (PDAC), the most common and aggressive form of the disease, which has historically resisted both chemotherapy and immunotherapy due to its dense, immune-suppressive tumor environment, writes NBC News.
One of the most closely watched efforts comes from BioNTech, which is developing an individualized mRNA-based vaccine known as autogene cevumeran. The treatment is tailored to each patient using genetic sequencing of their tumor to identify specific mutations, or neoantigens, that can be targeted by the immune system.
Pancreatic cancer has one of the most suppressive tumor microenvironments in oncology.
But two pancreatic cancer results dropped today. Both matter.
1. BioNTech mRNA neoantigen vaccine: nearly all responders still alive at 6 years. 98% of induced T cells were de novo — the… pic.twitter.com/W4qi6Qn6Hn
— Bo Wang (@BoWang87) April 20, 2026
In a small Phase 1 study involving 16 patients who underwent surgery for pancreatic cancer, the vaccine was administered alongside immunotherapy and chemotherapy. According to findings also reported in NBC News, the vaccine triggered new, tumor-specific immune responses in half of the participants—responses that were not present prior to treatment.
Patients who mounted these immune responses showed significantly improved outcomes. Most remained alive several years after treatment, with some follow-up extending beyond four to six years. By contrast, non-responders experienced earlier recurrence of disease.
Researchers found that the vaccine generated durable populations of CD8+ T cells—immune cells capable of targeting cancer—that persisted for years and adopted characteristics associated with long-term immune memory. The results suggest that the mRNA platform, widely known for its role in COVID-19 vaccines, may be capable of overcoming pancreatic cancer’s resistance to immune attack.
A larger, randomized Phase 2 trial is now underway to determine whether these early findings can be replicated in a broader patient population.
In parallel, a separate line of research is targeting one of the most elusive drivers of pancreatic cancer: mutations in the KRAS gene. These mutations are present in more than 90% of pancreatic tumors, with a specific variant known as G12D accounting for a substantial share.
A new oral drug, daraxonrasib, developed by Revolution Medicines, is designed to inhibit the active form of KRAS proteins—something that had long been considered beyond the reach of drug therapy.
Early-phase clinical data show the drug achieved a 47% response rate in patients receiving it as a first-line treatment for KRAS G12D-mutant pancreatic cancer, with disease control observed in more than 90% of cases. In previously treated patients, response rates were lower but still notable, and progression-free survival extended several months beyond typical expectations.
The therapy works by binding to the active, GTP-bound state of RAS proteins, effectively shutting down the signaling pathways that drive tumor growth. Side effects reported so far include rash, diarrhea, nausea, and fatigue, but have generally been manageable.
Experts say the two approaches—one activating the immune system, the other directly targeting tumor biology—represent complementary strategies in a disease that has seen few breakthroughs over the past several decades.
“Pancreatic cancer has one of the most suppressive tumor microenvironments in oncology. But two pancreatic cancer results dropped today. Both matter,” said University of Toronto professor Bo Wang. “Different mechanisms. Same disease. Both working. <13% of patients survive 5 years. That number is about to change. Great day for science!”
Still, researchers caution that both therapies remain in early stages of development. The vaccine study involved a small number of patients, and the KRAS inhibitor is still being evaluated in larger, late-stage trials. Questions also remain about why only some patients respond to immunotherapy and how best to combine these treatments for maximum benefit.
Even so, the results mark a shift in a field where progress has historically been slow. With additional trials underway and growing investment in personalized medicine and targeted therapies, scientists say the outlook for pancreatic cancer—once considered nearly untreatable—may finally be starting to change.
